Opioid Toxicity Following Concomitant Use of Macrolide Antibiotics with Fentanyl, Hydromorphone, or Oxycodone: A Population‐Based Study
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Tony Antoniou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Oxycodone, Analgesics, Opioid, Fentanyl, Hydromorphone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Fentanyl, hydromorphone, and oxycodone are metabolized by cytochrome P450 3A4 (CYP3A4). Co‐administration with CYP3A4‐inhibiting macrolides (clarithromycin or erythromycin) may increase opioid concentrations and overdose risk, but the clinical impact of these interactions is unknown. We conducted three population‐based nested case‐control studies of Ontario residents aged 15 years or older who were prescribed transdermal fentanyl, oral hydromorphone, or oral oxycodone between 1997 and 2023. We defined cases as individuals who died of or were hospitalized with opioid toxicity and matched each case to up to four controls on age, sex, calendar year, and a disease risk score. We assigned controls random index dates based on the distribution among cases and estimated adjusted odds ratios (aOR) and 95% confidence intervals (CIs) for the association between opioid toxicity and macrolide use in the preceding 14 days. We matched 735 fentanyl‐treated (45.3% of eligible cases), 2,506 hydromorphone‐treated (64.5%), and 678 oxycodone‐treated (50.1%) individuals with opioid toxicity to at least one control. Across all studies, 70 cases and 120 controls were exposed to a macrolide. CYP3A4‐inhibiting macrolide exposure was associated with an increased risk of opioid toxicity among patients treated with fentanyl (aOR 3.80, 95% CI: 1.36–11.56), hydromorphone (aOR 3.38, 95% CI: 1.28–8.97), and oxycodone (aOR 3.11, 95% CI: 1.05–9.51). We observed no associations with azithromycin, a non‐CYP3A4 inhibiting macrolide. There was no significant effect modification by study period, and findings were robust in bias analyses. These findings likely extend to individuals exposed to clandestinely produced fentanyl and to other CYP3A4 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.
- ICES, Toronto, Ontario, Canada.
- Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Schlegel Research Institute for Aging, Waterloo, Ontario, Canada.
ORCID-Profile: Tony Antoniou, David N Juurlink, Joanne M-W Ho, Muhammad Mamdani, Fangyun Wu, Mina Tadrous, Tara Gomes
Zitieren
APA
Antoniou, T., Yang, J., Juurlink, D. N., Ho, J. M., Mamdani, M., Wu, F., Tadrous, M., & Gomes, T. (2026). Opioid Toxicity Following Concomitant Use of Macrolide Antibiotics with Fentanyl, Hydromorphone, or Oxycodone: A Population‐Based Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70267
Vancouver
Antoniou T, Yang J, Juurlink DN, Ho JM, Mamdani M, Wu F, et al. Opioid Toxicity Following Concomitant Use of Macrolide Antibiotics with Fentanyl, Hydromorphone, or Oxycodone: A Population‐Based Study. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70267
BibTeX
@article{Antoniou2026,
author = {Antoniou, Tony and Yang, Joanna and Juurlink, David N and Ho, Joanne M-W and Mamdani, Muhammad and Wu, Fangyun and Tadrous, Mina and Gomes, Tara},
title = {Opioid Toxicity Following Concomitant Use of Macrolide Antibiotics with Fentanyl, Hydromorphone, or Oxycodone: A Population‐Based Study},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70267}
}
EUVIMED